FacultyFaculty/Author Profile
Tom Anderton

Tom Anderton

Squire Patton Boggs

San Francisco, CA, USA


Tom Anderton is currently an attorney at Squire Patton Boggs.  He was formerly General Counsel, Secretary at Zonare Medical Systems and Vice President, Intellectual Property & Legal Affairs at Presido Pharmaceuticals.  Before Presidio, he was the Associate General Counsel and Chief Patent Counsel at Monogram Biosciences, Inc., where he built Monogram's IP portfolio which then was consistently recognized as one of the best IP portfolios in the US.  Before going to Monogram, Tom was the Lead Attorney, Oncology at Genencor, Inc. where he developed and implemented Genencor’s oncology IP portfolio and led the due diligence team in their in-licensing of BL22, a lymphoma compound developed in Ira Pastan’s lab at the NCI.  Prior to that, Tom was responsible for envisioning and creating the IP portfolio related to the 'virtual' kinase, phosphatase and protease genes that SUGEN cloned from J. Craig Ventner’s early human genome sequencing efforts.  He was also involved in developing the portfolio that relates to the current Pfizer compound SU11248 (SUTENT).  In private practice, Tom drafted and prosecuted some of the early VEGF-related patents.  Before working in the biotech arena, Tom was focused on appellate, constitutional and First Amendment law and was responsible for co-writing trial briefs in the ISKCON v. City of Los Angeles (Hare Krishna/LAX) First Amendment case(s). Tom earned a J.D. from the Vermont Law School, a B.S. in molecular biology from UCSD and an M.S. in Cancer Biology from Stanford University. He has been consistently recognized by his peers as one of the most influential Life Science attorneys in the United States.  He is a member of the State Bar of California and is registered to practice before the United States Patent and Trademark Office.
Share
Email

  • FOLLOW PLI:
  • twitter
  • LinkedIn
  • GooglePlus
  • RSS

All Contents Copyright © 1996-2017 Practising Law Institute. Continuing Legal Education since 1933.

© 2017 PLI PRACTISING LAW INSTITUTE. All rights reserved. The PLI logo is a service mark of PLI.